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Abstract 30 
Objective: SNPs identified from genome-wide association studies associate with 31 
lipid risk markers of cardiovascular disease. This study investigated whether 32 
these SNPs altered the plasma lipid response to diet in the ‘RISCK’ study cohort.   33 
Methods: Participants (n=490) from a dietary intervention to lower saturated fat 34 
by replacement with carbohydrate or monounsaturated fat, were genotyped for 35 
39 lipid-associated SNPs. The association of each individual SNP, and of the SNPs 36 
combined (using genetic predisposition scores), with plasma lipid concentrations 37 
was assessed at baseline, and on change in response to 24 weeks on diets.  38 
Results: The associations between SNPs and lipid concentrations were 39 
directionally consistent with previous findings. The genetic predisposition scores 40 
were significantly associated with higher baseline concentrations of plasma total 41 
(P=0.02) and LDL (P=0.002) cholesterol, triglycerides (0.001) and apolipoprotein 42 
B (P=0.004), and with lower baseline concentrations of HDL cholesterol 43 
(P<0.001) and apolipoprotein A-I (P<0.001). None of the SNPs showed significant 44 
association with the reduction of plasma lipids in response to the dietary 45 
interventions, with the exception of the HDL-C-predisposition score which was 46 
associated with a greater reduction in apolipoprotein A-I. There was no evidence 47 
of diet-gene interactions; however there were additive effects of low-fat diet and 48 
high genetic predisposition score to augment reductions in apo A-I.  49 
Conclusion: Increased genetic predisposition was associated with an 50 
unfavourable plasma lipid profile at baseline, but did not influence the 51 
improvement in lipid profiles by the low-saturated-fat diets. The exception was 52 
the unfavourable decrease in apo A-I, a principal component of HDL.  53 
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Introduction: 59 
Plasma lipids are risk factors for cardiovascular disease (CVD) and are known to 60 
be sensitive to dietary change (1). Plasma cholesterol can be altered by changes 61 
to the quality and quantity of fat in the diet; in particular total plasma cholesterol 62 
can be lowered by reductions in dietary total or saturated fat (2, 3). However, 63 
replacement of SFA with carbohydrate also reduces HDL cholesterol (HDL-C) with 64 
an associated increase in CVD risk (4). Replacement of SFA with 65 
monounsaturated fatty acids (MUFA) achieves a decrease in total (TC) and LDL 66 
cholesterol (LDL-C) without a decrease in HDL-C (4, 5). Genetic factors also exert 67 
a strong influence on the regulation of plasma lipids, with heritability estimates 68 
for fasting plasma lipids ranging from 35–60% (6-8). There is growing interest in 69 
the interplay between genetic and environmental factors, which may help to 70 
explain the variation between individuals in response to diet (6). 71 
 72 
Genome-wide association (GWA) studies have identified a number of SNPs 73 
robustly associated with traits of dyslipidaemia in cross-sectional studies (9-16). 74 
However, it remains unknown whether these common lipid-associated SNPs also 75 
alter the responses to dietary interventions. We hypothesised that the 76 
mechanisms underlying genetic predisposition to dyslipidaemia would impair the 77 
improvement in plasma lipid status which can be produced by modifying the 78 
amount and type of dietary fat. This hypothesis was tested in a cohort of 490 79 
participants in the RISCK trial; a highly-controlled intervention to reduce dietary 80 
saturated fat based on replacement with either carbohydrate (CHO) or 81 
monounsaturated fat (MUFA) (2). We examined the association of 39 lipid-82 
associated SNPs, individually as well as combined, on plasma lipid measures at 83 
baseline and on the change in response to 24 weeks dietary intervention.  84 
 85 
Methods:  86 
Original RISCK trial study design 87 
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Full details of the RISCK trial have been published elsewhere (2). Briefly, men 88 
and women aged 30-70 years (n = 720) were recruited from the general 89 
population. To participate in the trial, subjects had to be at increased risk of 90 
developing metabolic syndrome and CVD according to a study-specific scoring 91 
system (2). Self-reported ethnicity was recorded as White; South and South East 92 
Asian, Black African, or other.  93 
The reference and intervention diets (described in detail in Moore et al. (17)) 94 
were designed to be iso-energetic, but varied in the amount and type of fat and 95 
carbohydrate. For the purposes of the current study the dietary intervention 96 
groups differing in carbohydrate quality were combined to focus the analyses on 97 
the manipulation of dietary fat, from which the impact in CVD risk was expected 98 
to be greater. The resulting three dietary groups were; ‘reference diet’ (REF) 99 
designed to reflect saturated fat intake in a ‘Western diet’ (~18% of energy (E) 100 
SFA, 12% MUFA, 38% total fat, 45% CHO); ‘MUFA diet’ in which SFA was reduced 101 
and replaced  with MUFA (~10% SFA, 20% MUFA, 38% total fat, 45% CHO);  ‘LF 102 
diet’, in which SFA was reduced through replacement of total fat with 103 
carbohydrate (~10% SFA, 11% MUFA, 28% total fat, 55% CHO).  104 
All participants underwent a 4 week run-in period on the REF diet, after which 105 
anthropometry was measured and fasting blood samples were taken. 106 
Measurements taken after the run-in diet are referred to in this study as 107 
‘baseline’ measurements. All participants followed their randomly prescribed diets 108 
for 24 weeks, after which a further blood sample was collected and 109 
anthropometry measured.  110 
Ethical approval for the RISCK study (ISRCTN29111298) was granted from the 111 
National Research Ethics Service and written informed consent from participants 112 
was obtained including subsequent genetic analyses. 113 
 114 
Characteristics of study cohort 115 
 5 
Of the 720 participants, 549 completed the study and DNA was available for 512 116 
participants. Based on self-reported ethnicity, we distinguished individuals of 117 
White (80%), South and South East (S, SE) Asian (9.5%); Black African (8%) 118 
and “other” (2.5%) ancestry. Analyses were stratified by self-reported ethnicity 119 
into three sub-groups with participants in the “other” subgroup excluded from this 120 
analysis (n=11). The characteristics of the participants in this study, stratified by 121 
the three main ethnic groups, are presented in Table 1.   122 
The majority (91%) of the participants were overweight or obese and/or had 123 
elevated waist circumference (>94 cm for males and >84 cm for females) 124 
indicating the presence of central obesity.  125 
We observed no significant differences for age, gender, BMI, body fat (%), waist 126 
circumference, triglycerides, HDL-C, apo B or apo A-I between the ethnic groups. 127 
Glucose concentrations were lower in S,SE Asians compared to Whites, insulin 128 
concentrations were higher in Black-Africans compared to Whites, and TC lower in 129 
Black-Africans compared to Whites (Table 1).  130 
 131 
Plasma lipid analyses and response to dietary intervention 132 
TC, HDL-C and triglyceride (TG) were analysed at King’s College London by 133 
enzymatic assay on a Bayer Advia Model Analyser using reagents supplied by the 134 
manufacturer (Bayer Diagnostics Europe, Newberry, Berks, UK). LDL-C was 135 
calculated using the Friedwald formula only it fasting TG concentrations were 136 
<4.49 mmol/L. Plasma apolipoproteins B (apo B) and A-I (apo A-I) were 137 
determined by immunoprecipitation assays (Randox Laboratories, Crumlin, UK) at 138 
the University of Surrey (see Jebb et al. (2) for further details). 139 
 140 
As reported in full in Jebb et al. (2) plasma TC, LDL-C and apo B were 141 
significantly reduced in response to 24 weeks on the LF and MUFA diets. There 142 
was also a significant reduction in plasma HDL-C and apo A-I in response to the 143 
LF but not the MUFA diet. There was no change in plasma TG.  144 
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 145 
SNP selection and genotyping 146 
Forty lipid-associated SNPs were identified from GWA studies published prior to 147 
April 2009. SNPs were only selected from GWA studies with at least 1000 148 
individuals in the discovery stage, with replication in at least one independent 149 
population, and which reached the threshold of genome-wide significance of P<5 150 
x 10-8 (9-16). Priority was given to SNPs that were plausible biological targets of 151 
lipid metabolic pathways, and that were identified by at least two independent 152 
GWA studies or meta-analyses. Where multiple SNPs resided in or near the same 153 
gene, SNPs in low linkage disequilibrium (LD r2<0.3) were selected with a 154 
maximum of three SNPs per gene.  155 
Genotyping was performed in the 501 participants of the three main ethnic 156 
groups who completed the study, and for which there was DNA available. 157 
Genotyping was performed by KBiosciences (Hoddesdon, Herts, UK) using a 158 
fluorescence-based competitive allele-specific PCR (KASPar) technology and all 159 
SNPs had a call rate >95%. Individuals were excluded if genotyping was 160 
unsuccessful in >10% of SNPs (11 subjects). All genotype distributions were 161 
tested for deviation from the Hardy-Weinburg Equilibrium using the Log likelihood 162 
ratio chi-square test for association (P<0.001); and one SNP was excluded 163 
(rs174547) from analyses due to deviation (P<0.0001).  This resulted in 14 HDL-164 
C-associated SNPs in or near 11 genes; 12 LDL-C-associated SNPs in or near 11 165 
genes; five TC-associated SNPs in or near five genes; and ten TG-associated 166 
SNPs in or near nine genes (Supplementary Table 1). Some SNPs were 167 
associated with more than one lipid trait.  168 
 169 
Genetic Predisposition Score  170 
A risk-allele was defined as the allele associated with raised TC, LDL-C, TG or low 171 
HDL-C in previous GWA studies (9-16). An additive model was assumed and 172 
individual SNPs were coded as 0, 1 and 2 on the basis of the number of the risk-173 
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alleles for that particular SNP based on previous GWA studies (9-16). As there is 174 
currently no evidence for interaction between SNPs, a simple addition of the 175 
associated risk alleles for each trait has been commonly adopted (18-20). For 176 
each individual, genetic predisposition scores (GPS) were calculated for each of 177 
the traits separately (HDL-C, LDL-C, TC, TG) by adding all of the scores for each 178 
risk-allele associated with that trait (Supplementary Table 1). For participants 179 
missing individual genotyping data, the average count of risk alleles for the 180 
respective SNP was substituted for the missing genotype for the purposes of 181 
calculating the GPS. All GPS were normally distributed.  182 
The SNPs selected for analysis are presented in Supplementary Table 1 183 
showing the risk-allele frequency in each ethnicity for this cohort. Previous 184 
studies have shown that LDL-C-associated SNPs also associate with apo B and 185 
HDL-C-associated SNPs associate with apo A-I (16, 18). Therefore LDL-C-186 
associated SNPs and LDL-C GPS were also used to examine the effect on apo B 187 
and HDL-C-associated SNPs and HDL-C GPS were used to assess the association 188 
with apo A-I.  189 
 190 
Statistical Analysis 191 
Distributions of traits were tested for normality; and baseline TG was log-192 
transformed for analyses and presented in tables in this form.  193 
Linear regression analysis was used to test for associations between each SNP 194 
(coded as 0,1 and 2 according to the number of risk-alleles) and the relevant 195 
traits at baseline, assuming an additive effect of each additional risk allele, while 196 
adjusting for age, gender and BMI. Next, we tested for association between each 197 
SNP and change in lipid concentration following 24 weeks of intervention, 198 
adjusted for baseline values of respective trait, age, gender and BMI. There was 199 
no linearity assumption of relevant traits with diet, so each diet was added in the 200 
model individually.  201 
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Associations between the GPSs and respective traits (baseline and change) were 202 
tested with linear regression in the same way individual SNPs were tested, 203 
adjusting for the same covariates.  204 
All analyses were stratified by the three main ethnic groups. Summary statistics 205 
of the ethnicity-specific associations were pooled using inverse-variance fixed 206 
effects meta-analysis (metan function in stata) and heterogeneity between the 207 
ethnicities was assessed by I2 statistic. 208 
Statistical analysis was conducted using Stata 11 (StataCorp, Texas, USA).  209 
 210 
Results 211 
 212 
Effect of genetic predisposition on lipids and apolipoproteins at baseline 213 
The trait-specific GPSs were all significantly associated with the respective traits; 214 
i.e. the higher the score the less favourable the lipid profile (Table 2). Each 215 
additional risk-allele in the TC-GPS was associated with 0.08 mM higher TC 216 
concentration; the LDL-C-GPS was associated with a 0.06 mM higher LDL-C 217 
concentration per additional risk-allele and the TG-GPS with a 0.04 mM higher 218 
lnTG concentration per additional risk-allele (Table 2).  219 
The LDL-C-GPS was also associated with higher apo B concentration and the HDL-220 
C-GPS with lower apo A-I levels per additional risk allele (Figure 1).  221 
 222 
We observed directionally consistent associations for four out of five individual TC 223 
SNPs, of which one reached nominal significance; for nine out of 12 LDL-C SNPs, 224 
of which two reached nominal significance; for nine out of 13 HDL-C SNPs of 225 
which four reached nominal significance; and for five out of seven TG SNPs of 226 
which three reached nominal significance, when data of all three ethnic groups 227 
were combined (Supplementary Table 2). 228 
Ten out of 12 LDL-C risk SNPs, were positively associated with apo B 229 
(Supplementary Figure 1a), of which two reached nominal significance 230 
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(Supplementary Table 2). Eleven out of 13 HDL-C risk SNPs were negatively 231 
associated with apo A-I (Supplementary Figure 1b), six of which reached 232 
nominal significance, four of which were also significantly negatively associated 233 
with HDL-C (rs1800775 and rs9989419 - CETP locus; rs10468017 - LIPC locus; 234 
rs4846914 - GALNT2 locus).  235 
There was little evidence of heterogeneity between the ethnic groups except two 236 
TG SNPs and one HDL-C SNP that was directionally consistent in Whites and S,SE 237 
Asians but not in Black Africans (Supplementary Table 2).  238 
 239 
Effect of genetic predisposition on the change in lipids and apolipoproteins in 240 
response to dietary intervention to lower SFA 241 
Following the dietary intervention, the decrease in apo A-I was significantly 242 
greater the higher the HDL-C GPS, with an effect size of -0.01 g/L per HDL-C risk 243 
allele (P<0.05) (Table 3). The reducing effects of the LF diet and HDL-C-GPS 244 
were additive (Figure 2) but there was no significant diet x GPS interaction effect 245 
for apo A-I (P>0.09 for all ethnicities) or any other traits (data not shown). TC 246 
tended (P=0.1) to be further reduced by 0.03 mM per allele with higher TC-GPS 247 
(Table 3). There was also a trend (P=0.09) towards a greater reduction in HDL-C 248 
of 0.01 mM per allele with higher GPS. GPS was not associated with change in TG 249 
or with reduction of LDL-C or apo B (Table 3).  250 
There was no evidence of heterogeneity across the three ethnic groups for the 251 
effect of GPS on the change in lipid or apolipoprotein traits. 252 
 253 
Of the five TC SNPs, one in the APOB locus tended (P=0.06) to augment the diet-254 
induced reductions in TC levels; of the 11 LDL-C SNPs, only one in the PCSK9 255 
locus was significantly (P=0.04) associated with impeding the diet-induced 256 
reductions in LDL-C. No individual SNPs were associated with change in HDL-C, 257 
TG, apo B or apo A-I following the dietary intervention (Supplementary Table 258 
3).  259 
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There was some indication (P<0.1) of heterogeneity between the ethnic groups 260 
for the effect of individual SNPs on change in traits with one TC SNP on the 261 
change in TC; 1 LDL-C SNP on the change in LDL-C and four on the change in apo 262 
B; one HDL-C SNP on change in HDL-C and two on change in apo A-I 263 
(Supplementary Table 3). Generally, associations were directionally consistent 264 
between the Whites and S,SE Asians but not Black-Africans.   265 
 266 
While the intervention diets were designed to be iso-energetic, there was a 267 
significant (P<0.001) incidental weight loss on the low fat diet during the trial (2). 268 
As weight loss has been shown to improve lipid profiles (21), the analyses were 269 
repeated with and without weight change. There was no difference in the effect of 270 
SNP or GPS on change in plasma lipids (data not shown).  271 
 272 
Discussion 273 
 274 
Our results show the genetic predisposition scores were significantly associated 275 
with the respective lipid trait at baseline on a ‘habitual’ diet high in SFA. We also 276 
confirmed that many of the SNPs identified in GWA studies showed directionally 277 
consistent associations with lipid traits, and with effects of a similar magnitude in 278 
this cohort of subjects at increased cardiometabolic risk. We found no evidence 279 
that genetic predisposition to dyslipidaemic traits impaired the beneficial effects 280 
of a dietary intervention of reduced SFA intake to lower plasma TC, LDL-C and 281 
apo B. Furthermore, there was a tendency for greater improvements in plasma 282 
TC the higher the genetic predisposition to raised TC. However, unfavourable 283 
reductions in HDL-C and apo A-I were augmented by genetic predisposition to low 284 
HDL-C. This was an exploratory analysis in a relatively small cohort, but the 285 
results from this analysis suggests that further research is warranted to explore 286 
the role of these common SNPs as ‘effect modifiers’ in dietary intervention studies 287 
to improve plasma lipids and apoproteins.  288 
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 289 
Very few studies have examined the relationship between commonly occurring 290 
SNPs and plasma apolipoproteins. Previous GWA studies (16) and studies using 291 
the CardioChip (18) showed a close association between LDL-C-SNPs and apo B 292 
and HDL-C-SNPs and apo A-I. In the RISCK study cohort, we have shown that a 293 
cumulative GPS, composed of LDL-C-SNPs, was positively associated with apo B 294 
and that a cumulative GPS composed of HDL-C-SNPs was negatively associated 295 
with apo A-I at baseline. In response to 24 weeks dietary intervention both the LF 296 
diet and the HDL-C-GPS were significantly associated with a reduction in apo A-I. 297 
Although not significant, the association of GPS on change in HDL-C (P=0.09) was 298 
also negative. A disadvantage of a low fat diet can be a resultant decrease in 299 
HDL-C (4), as low HDL-C and apo A-I are in themselves markers of metabolic 300 
syndrome and CVD risk (22-24). This study shows that those genetically 301 
predisposed to low HDL-C, and who also have low apo A-I may have further 302 
adverse effects on lipid profile following a LF diet. 303 
 304 
In this study, the opportunities to examine single SNPs were limited due to small 305 
sample size and the small effect size of the SNPs. Many of the selected SNPs were 306 
located in or near genes involved in lipid metabolic pathways (6). Many SNPs 307 
were also located in genes where rare monogenic mutations underlie causes of 308 
severe dyslipidaemia (25). Notably, SNPs of CETP (Cholesteryl Ester Transfer 309 
Protein) and LIPC (hepatic lipase) loci were significantly associated with baseline 310 
HDL-C and apo A-I as found previously both in GWA studies (9, 11, 13, 16) and 311 
in candidate gene studies (26, 27). However, these individual SNPs did not 312 
significantly alter the HDL-C and apo A-I response to dietary intervention. The 313 
rs4846914 SNP from the GALNT2 locus was also significantly associated with both 314 
baseline HDL-C and apo A-I in the current study. An association between this SNP 315 
and HDL-C was recently reported in a large meta-analysis of GWA studies of 316 
common variants and lipid traits, with follow-up functional studies in mice that 317 
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implicated GALNT2 as a biological mediator of HDL-C concentration (28). In the 318 
current study, there was also no association of this SNP with change in apo A-I, 319 
but it was associated with a significant increase (0.03 ± 0.01 mM, P=0.03) in 320 
HDL-C in the White participants only, indicating a potential cardio-protective 321 
effect (Supplementary Table 2).  322 
 323 
In the current study, there was little evidence of heterogeneity for individual SNPs 324 
or GPS on lipid traits between different ethnic groups, which is consistent with a 325 
recent large study that showed no evidence of heterogeneity between European, 326 
South and South-East Asian and African American populations in 95 lipid-related 327 
SNPs (28).  There was a greater degree of heterogeneity between ethnic groups 328 
in the effects of SNPs on the change in lipid traits, however this finding can only 329 
be viewed as exploratory in view of the very small sample size of the Asian and 330 
Black subgroups. Nevertheless there was evidence that the effects of some SNPs 331 
in response to diets were greater in some ethnicities. For example SNPs rs693 332 
(APOB locus) and rs3846662 (HMGCR locus) had a significantly greater reduction 333 
in plasma TC (effect size -0.26 and -0.31 mM per risk allele) in Black-Africans 334 
group but no significant effect in Whites (supplementary Table 3). As many of 335 
the SNPs reside outside coding regions of the genes, this may reflect that these 336 
SNPs were simply markers for other SNPs, and that the LD between the marker 337 
and functional SNP varies with ethnicity (29). This warrants further investigation 338 
in larger cohorts.  339 
 340 
In conclusion, high plasma TC, TG, LDL-C and apo B and low apo A-I and HDL-C 341 
were influenced by genetic predisposition in this cohort of overweight men and 342 
women, who were identified at increased cardiometabolic risk. A dietary 343 
manipulation to lower SFA was successful in lowering plasma TC, LDL-C, and apo 344 
B, most notably in those genetically predisposed to dyslipidaemia. Conversely, 345 
genetic predisposition to a low plasma apo A-I, and possibly HDL-C, is 346 
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exacerbated in overweight subjects when dietary saturated and total fat is 347 
reduced in exchange for carbohydrate.  348 
 349 
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Figure 1 377 
(a) Variation of apo B at baseline by LDL-C genetic predisposition score (GPS) and 378 
(b) Variation of apo A-I at baseline by HDL-C genetic predisposition score (GPS). 379 
The squares represent the mean and standard error values of (a) apo B and (b) 380 
apo A-I (right y-axes) for each GPS score category defined by the number of (a) 381 
LDL-C and (b) HDL-C risk alleles per individual (x-axes). The histograms denote 382 
the number of individuals in each GPS score category (left y-axes).  383 
 384 
Figure 2 385 
Apo A-I stratified by genetic predisposition score (GPS) before and after the 386 
dietary intervention in the total cohort, and split into dietary intervention groups. 387 
Data are presented as mean ± SE before and after 24 weeks on a dietary 388 
intervention for a) the response in the total cohort and split into b) the REF diet 389 
group; c) the high MUFA diet group; and d) the LF diet group. HDL-C-GPS was 390 
stratified into 4 groups [≤11; 12-13; 14-15; ≥16 risk alleles]. The number of 391 
subjects in each group was as follows: Total (GPS-1:129, GPS-2:138, GPS-3:149, 392 
GPS-4:53); REF (GPS-1:17, GPS-2:28, GPS-3:22, GPS-4:9); MUFA (GPS-1:58, 393 
GPS-2:54, GPS-3:57, GPS-4:29); LF(GPS-1:54, GPS-2:56, GPS-3:70, GPS-4:15). 394 
 395 
Supplementary Figure 1 396 
The effect of LDL-C-associated SNPs on apo B (a) and HDL-C-associated SNPs on 397 
apo A-I (b) at baseline.  398 
Data are presented as the effect size ± 95% CI from the meta-analysis of 399 
summary statistics from linear regression analyses performed in the three 400 
ethnicities between (a) individual LDL-C-SNPs and apo B and (b) individual HDL-C 401 
SNPs and apo A-I at baseline. The models were adjusted for age, gender and 402 
BMI.  403 
Nominally significant (P<0.05) associations are in black symbols. 404 
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† rs1800588 (LIPC) was significantly heterogeneous (P<0.0001) for the 3 405 
ethnicities, the meta-analysed data for the White and Asian subgroups only 406 
(Heterogeneity = 0.256) are presented for this SNP.  407 
 408 
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